Clinical Results with Humanized and Human Monoclonal Antibodies

  • James B. Cornett
Part of the The Sixth International Meeting of Japanese Association for Animal Cell Technology JAACT’93 book series (ANICELLTECH, volume 6)


Monoclonal antibodies (MAbs) from animals may be humanized by the process of “CDR grafting”. However, the CDRs from a murine MAb that are inserted into a human MAb framework may not retain their original shape. When this occurs, the humanized MAb will no longer bind the original target antigen. A computer-assisted molecular modeling procedure has been developed to overcome this inherent difficulty. More than a dozen murine MAbs have been humanized using this procedure which has permitted the humanized MAbs to retain their antigen binding ability. Two murine MAbs humanized by this procedure, SMART Anti-Tac (anti-CD25 / IL-2r) and SMART M195 (anti-CD33), have been entered into clinical trials. Relative to their murine counterparts, the humanized MAbs showed longer serum half-lives, improved effector cell function and, most importantly, were not immunogenic in humans. Nearly 40 patients have received single or multiple doses of these humanized MAbs and in some cases up to 12 doses have been administered over a period of 4 months with no immunogenic response. These clinical results to date, along with those with human (anti-viral) MAbs, indicate that humanized and human MAbs are capable of overcoming the disadvantages of short serum half-life and immunogenicity of murine MAbs.


Human Monoclonal Antibody Bone Marrow Transplant Patient Murine Antibody Human Myeloma Cell Line Smart Process 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. [1]
    Köhler G & Milstein C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497.PubMedCrossRefGoogle Scholar
  2. [2]
    Khazaeli, MB, Conroy RM & LoBuglio AF. (1994) Human immune response to monoclonal antibodies. J Immunother 15:42–52.CrossRefGoogle Scholar
  3. [3]
    Morrison SL, Johnson M, Huzenberg L & Oi V. (1984) Chimeric human antibody molecules: mouse antigen-binding domains with huyman constant region domains. Proc Natl Acad Sci USA 81:6851–6855.PubMedCrossRefGoogle Scholar
  4. [4]
    Riechmann L, Clark M, Waldmann H & Winter G. (1988) Reshaping human antibodies for therapy. Nature 332:323–327.PubMedCrossRefGoogle Scholar
  5. [5]
    Jones PT, Dear PH, Foote J, Neuberger MS & Winter G. (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522–525.PubMedCrossRefGoogle Scholar
  6. [6]
    Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP & Waldmann TA. (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 86:10029–10033.PubMedCrossRefGoogle Scholar
  7. [7]
    Vasquez M & Payne PW. (1993) Computational approaches to the design of therapeutic antibodies with enhanced clinical efficacy. Chem Design Automation News November/December.Google Scholar
  8. [8]
    Uchiyama T, Broder S & Waldmann TA. (1981) A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J. Immunol. 126:1393–1397.PubMedGoogle Scholar
  9. [9]
    Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP & Waldmann TA. (1989) A humanized antibody that binds to the interleukin-2 receptor. Proc Natl Acad Sci USA 86:10029–10033.PubMedCrossRefGoogle Scholar
  10. [10]
    Anasetti C, Hansen JA, Waldmann T, Binger M-H, Mould D, Satoh H, Appelbaum FR, Deeg HJ, Doney K, Martin PJ, Nash R, Sullivan KM, Witherspoon RP & Storb R. (1992) Treatment of acute graft-versus-host disease with a humanized monoclonal antibody specific for the IL-2 receptor. Blood 80(suppl 1): 373a.Google Scholar
  11. [11]
    Scheinberg DA, Tanimoto M, McKenzie S, Strife A, Old LJ & Clarkson BD. (1989) Monoclonal antibody M195: A diagnostic marker for acute myelogenous leukemia. Leukemia 3:440–445.PubMedGoogle Scholar
  12. [12]
    Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ, Larson SM & Scheinberg DA. (1993) Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 11:294–303.PubMedGoogle Scholar
  13. [13]
    Caron PC, Co MS, Bull MK, Avdalovic NM & Scheinberg DA. (1992) Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 52:6761–6767.PubMedGoogle Scholar
  14. [14]
    Caron PC, Jiurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, Jureidini IM, Sgouros G, Tyson D, Old LJ, Larson SM & Scheinberg DA. (1994) A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood (in press).Google Scholar
  15. [15]
    Olssson L & Kaplan HS. (1990) Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. Proc Natl Acad Sci USA 77:5429–5431.CrossRefGoogle Scholar
  16. [16]
    Östberg L & Pursch E. (1983) Human x (mouse x human) hybridomas stably producing human antibodies. Hybridoma 2:361–367.PubMedCrossRefGoogle Scholar
  17. [17]
    Dunkel EC, Siegel ML, Brooks J, Tolpin MD, Magid P, Freitas D & Pavan-Langston D. MSL-109 therapy of human cytomegalovirus-induced chorioretinitis in the rabbit. Antiviral Res 15 (Suppl 1):121.Google Scholar
  18. [18]
    Nadler P, Wood DL, Östberg L & Co MS. (1994) The use of human and genetically engineered “humanized” antibodies for the prophylaxis and treatment of cytomegalovirus infection. Transplantation & Immunology Lett IX:5-6, 13–15.Google Scholar
  19. [19]
    Autlitzky WE, Schulz TF, Tilg H, Niederwieser D, Larcher K, Östberg L, Scriba M, Martindale J, Stern AC, Grass P, Mach M, Dierich MP & Huber C. (1991) Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: report of a phase i trial in bone marrow transplant patients. J Infect Dis 163:1344–1347.CrossRefGoogle Scholar
  20. [20]
    Drobyski WR, Gottlieb M, Carrigan D, Östberg L, Grebenau M, Schran H, Magid P, Ehrlich P, Nadler PI & Ash RC. (1991) Phase I study of safety and pharmacokinetics of a human anticytoegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. Transplantation 51: 1190–1196.PubMedCrossRefGoogle Scholar
  21. [21]
    Pollard RB, et al, Antiviral Res 1992; 16: (Suppl 1): 111.Google Scholar
  22. [22]
    Tolpin M, Pollard R, Tierney M, Nokta M, Wood D & Hirsch M. (1993) Combination therapy of cytomegalovirus (CMV) retinitis with ahuman monclonal anti-CMV antibody (SDZ MSL 109) and either ganciclovir (DHPG) or foscarnet (PFA). Prox IX International Conference on AIDS, 1993.Google Scholar
  23. [23]
    Ehrilich PH, Moustafa ZA, Justice JC, Harfeldt E, Kelley RL & Östberg L. (1992) Characterization of human monoclonal antibodies directed against hepatitis B surface antigen. Hum Antibod Hybrdomas 3:2–7.Google Scholar
  24. [24]
    Ogata N, Östberg L, Ehrlich PH, Wong DC, Miller RH & Purcell RH. (1993) Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen. Proc Natl Acad Sci USA 90:3014–3018.PubMedCrossRefGoogle Scholar
  25. [25]
    Fung J, Östberg L, Shapiro R, Todo S, Demetris A & Starzl T. (1993) A trial of human monoclonal antibody against hepatitis B surface antigen in prevention of recurrent hepatitis B following liver transplantation.Google Scholar
  26. [26]
    McMahon G, Ehrlich PH, Moustafa ZA, McCarthy LA, Dottavio D, Tolpin MD, Nadler PI & Östberg L. (1992) Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 15:757–766.PubMedCrossRefGoogle Scholar
  27. [27]
    Paar DP, Nadler P, Schiff ER & Pollard RB. (1994) A phase I/II open-label study to assess the safety, pharmacokinetic profile, and preliminary antiviral effects of OST-577 (a human anti-hepatitis B surface antigen monoclonal antibody) administered to patients who are persistently hepatitis B antigen seropositive. Abstract; Seventh International Conference on Antiviral Research, Charleston, South Carolina.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1994

Authors and Affiliations

  • James B. Cornett
    • 1
  1. 1.Protein Design Labs, Inc.Mountain ViewUSA

Personalised recommendations